About | Free Trial

Last Update

2012-05-16T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Donald Hayden?

Mr. Donald Hayden J. Jr.

Chairman

Insmed Incorporated

Direct Phone: (804) ***-****       

Email: d***@***.com

Insmed Incorporated

9 Deer Park Drive Suite C

Monmouth Junction, New Jersey 08852

United States

Company Description

Insmed Incorporated (Insmed) is a development stage biopharmaceutical company specializing in recombinant protein drug development. The Company also engaged the services of RBC to act as financial advisor. On March 31, 2009, the Company completed the sale ... more

Find other employees at this company (216)

Background Information

Employment History

Lead Independent Director
AMICUS THERAPEUTICS INC

Executive Vice President and President, Americas
Bristol-Myers Squibb Company

Affiliations

Senior Advisor
Prospect Venture Partners

Board of Trustees Member
Cancer Care , Inc.

Board Member
Satori Pharmaceuticals Incorporated

Education

BA

Harvard University

Masters of Business Administration degree

Indiana University

undergraduate degree

Harvard University

Web References (196 Total References)


Insmed Appoints Donald J. Hayden, ...

www.prsyndication.com, $reference.date [cached]

Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman 16 May 2012 MONMOUTH JUNCTION, N.J., May 16, 2012 -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall Whitcomb, M.D. as the Lead Independent Director, effective immediately.  Mr.


Insmed Appoints Donald J. Hayden, ...

www.prsyndication.com, $reference.date [cached]

Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman

Insmed Appoints Donald J. Hayden, Jr. as Executive Chairman Wednesday, May 16, 2012
MONMOUTH JUNCTION, N.J., May 16, 2012 -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall Whitcomb, M.D. as the Lead Independent Director, effective immediately.  Mr.
...
In 2010, Mr. Hayden became Chairman of Insmed following the merger with TransaveHe had previously served as Executive Chairman of Transave since April 2006.   Mr. Hayden also currently serves as Lead Independent Director of Amicus Therapeutics and Director of Otsuka Pharmaceuticals.  He also serves in Board roles for several privately-held companies, including Executive Chairman of Azelon Pharmaceuticals, Chairman of Vitae Pharmaceuticals and Satori Pharmaceuticals, and Director of Nora Therapeutics.  Mr. Hayden is also a senior advisor to Prospect Venture Partners, a venture capital firm.  From 1981 to 2006, he had a 25 year career with Bristol-Myers Squibb Company, where he served in key executive roles such as President of Global Pharmaceuticals; Executive Vice President and President, Americas; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President of Worldwide Franchise Management and Business Development.  Mr. Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University.


Board of Directors - REGENXBIO

www.regenxbio.com, $reference.date [cached]

Don Hayden Chairman of the Board

Don Hayden brings experience and insight to the REGENXBIO Board. Mr. Hayden had a highly successful 25-year career with Bristol-Myers Squibb Company and continues to hold key roles at a number of entrepreneurial pharmaceutical and biotech companies.
At Bristol-Myers Squibb, he served as president of Global Pharmaceuticals; executive vice president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses; executive vice president of the Health Care Group; president of Oncology and Immunology; and senior vice president for Worldwide Franchise Management and Business Development. Since leaving Bristol-Myers Squibb in early 2006, he has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals, Nora Therapeutics, and Dimension Therapeutics.
Mr. Hayden received an M.B.A. from Indiana University and his undergraduate degree from Harvard University.


"David's expertise in clinical research ...

ir.regenxbio.com, $reference.date [cached]

"David's expertise in clinical research and development, as well as his experience advancing therapies through the regulatory process to FDA approval, will be of great value as REGENXBIO prepares to advance gene therapy treatments into the clinic," said Don Hayden, Chairman of REGEN...

...
"Jerry is an experienced biopharmaceutical leader who brings to REGENXBIO more than 20 years of success in key strategic, operational, commercial, research and development, and board roles," said Don Hayden, Chairman of REGENXBIO's board of directors.
...
Mr. Beshar will serve as the chairman of REGENXBIO's audit committee."Luke's strategic insights and deep financial expertise have contributed directly to the success of several biopharma companies," said Don Hayden, Chairman of REGENXBIO's board of directors.


Donald J. Hayden, Jr. Chairperson ...

ir.regenxbio.com, $reference.date [cached]

Donald J. Hayden, Jr. Chairperson

Similar Profiles

Other People with this Name (16,842)

Other people with the name Hayden

Michael Hayden
Central Intelligence Agency

C.W. Hayden
C.W. Hayden Co. Inc

Michael Hayden
BlueBloggin

Janice Hayden
DonorDrive

Erika Hayden
Nature

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory